DK0833611T3 - Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf - Google Patents
Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling herafInfo
- Publication number
- DK0833611T3 DK0833611T3 DK96921197T DK96921197T DK0833611T3 DK 0833611 T3 DK0833611 T3 DK 0833611T3 DK 96921197 T DK96921197 T DK 96921197T DK 96921197 T DK96921197 T DK 96921197T DK 0833611 T3 DK0833611 T3 DK 0833611T3
- Authority
- DK
- Denmark
- Prior art keywords
- glass
- active agent
- composition
- pct
- preparation
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 5
- 238000007496 glass forming Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 1
- 239000004014 plasticizer Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Processing Of Solid Wastes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502244A SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | A composition and a process for the preparation thereof |
| PCT/SE1996/000806 WO1997000670A1 (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0833611T3 true DK0833611T3 (da) | 2001-10-08 |
Family
ID=20398685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96921197T DK0833611T3 (da) | 1995-06-20 | 1996-06-19 | Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6083518A (da) |
| EP (1) | EP0833611B1 (da) |
| JP (1) | JP4020331B2 (da) |
| AT (1) | ATE204466T1 (da) |
| AU (1) | AU695622B2 (da) |
| CA (1) | CA2225286C (da) |
| DE (2) | DE69614689T2 (da) |
| DK (1) | DK0833611T3 (da) |
| ES (1) | ES2118677T3 (da) |
| NZ (1) | NZ311208A (da) |
| PT (1) | PT833611E (da) |
| SE (1) | SE9502244D0 (da) |
| WO (1) | WO1997000670A1 (da) |
| ZA (1) | ZA965237B (da) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136814A (en) * | 1997-12-08 | 2000-10-24 | Fujisawa Usa, Inc. | Aqueous acyclovir product |
| SE9801704D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
| SE9801705D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
| EP1216037A2 (en) * | 1999-09-21 | 2002-06-26 | Emory University | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| CA2359945C (en) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| JP4512700B2 (ja) * | 2003-06-02 | 2010-07-28 | トーアエイヨー株式会社 | アシクロビル含有水溶液製剤 |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| CA2560513A1 (en) | 2004-04-08 | 2005-12-01 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| GB2432528B (en) * | 2005-11-29 | 2011-04-06 | Ian Ripley | Anti-viral compositions comprising flavanone glycosides and fruit acids |
| KR101373955B1 (ko) * | 2006-03-08 | 2014-03-12 | 니혼노야쿠가부시키가이샤 | 외용의 의약 조성물 |
| BRPI0621446C1 (pt) * | 2006-03-08 | 2021-05-25 | Nihon Nohyaku Co Ltd | composição farmacêutica para uso externo |
| JP5184342B2 (ja) | 2006-03-08 | 2013-04-17 | 日本農薬株式会社 | 外用の医薬組成物 |
| KR20090031726A (ko) | 2006-06-14 | 2009-03-27 | 닥터 레디스 레보러터리즈 리미티드 | 국소용 조성물 |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| KR100721126B1 (ko) | 2006-12-28 | 2007-05-23 | (주)바이오앤에이치엔티 | 모기 기피제 조성물 |
| CN101808637B (zh) | 2007-09-05 | 2013-07-24 | 宝丽制药股份有限公司 | 医药组合物 |
| CN101808639B (zh) * | 2007-09-05 | 2012-12-05 | 宝丽制药股份有限公司 | 抗真菌医药组合物 |
| EP2191827B1 (en) * | 2007-09-05 | 2013-10-30 | Pola Pharma Inc. | Antifungal composition |
| JP5411141B2 (ja) | 2007-09-10 | 2014-02-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US20110027399A1 (en) * | 2008-03-31 | 2011-02-03 | Hiroshima University | Antiviral Agent and Antiviral Composition |
| GB2460915B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| US7906553B2 (en) | 2008-08-27 | 2011-03-15 | Calcimedica, Inc. | Substituted thiophene modulators of intracellular calcium |
| EP2385821B1 (en) * | 2009-01-09 | 2016-08-31 | Egis Gyógyszergyár Zrt. | Improved pharmaceutical formulation |
| EP2745692A1 (en) * | 2009-02-13 | 2014-06-25 | Topica Pharmaceuticals, Inc | anti-fungal formulation containing luliconazole |
| KR101409792B1 (ko) | 2009-04-09 | 2014-06-19 | 니혼노야쿠가부시키가이샤 | 항진균성 약제학적 조성물 |
| US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| WO2011024620A1 (en) | 2009-08-25 | 2011-03-03 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| ES2602475T3 (es) | 2010-04-15 | 2017-02-21 | Tracon Pharmaceuticals, Inc. | Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER |
| AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| DK2563776T3 (da) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Forbindelser, der modulerer intracellulært calcium |
| CA2806670A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
| US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| PL3104854T3 (pl) | 2014-02-10 | 2020-11-30 | Respivant Sciences Gmbh | Stabilizatory komórek tucznych do leczenia choroby płuc |
| WO2015164213A1 (en) | 2014-04-23 | 2015-10-29 | The Research Foundation For The State University Of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
| CN106572650B (zh) | 2014-06-10 | 2021-08-31 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
| US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| BR112017018198A2 (pt) | 2015-02-27 | 2018-04-10 | Curtana Pharmaceuticals Inc | inibição da atividade de olig2 |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| SG11201804776SA (en) | 2015-12-08 | 2018-07-30 | Biomatrica Inc | Reduction of erythrocyte sedimentation rate |
| WO2017147146A1 (en) | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
| AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| EP3463576A4 (en) | 2016-05-25 | 2020-01-15 | Concentric Analgesics, Inc. | PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2018039621A1 (en) | 2016-08-26 | 2018-03-01 | Curtana Pharmaceuticals, Inc. | Inhibition of olig2 activity |
| EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS |
| JP2019531308A (ja) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 肺線維症の治療のためのクロモリン組成物 |
| US11382897B2 (en) | 2017-11-07 | 2022-07-12 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
| WO2019094772A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| CN112040947A (zh) | 2017-12-07 | 2020-12-04 | 密歇根大学董事会 | Nsd家族抑制剂及用其进行治疗的方法 |
| US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
| EP3813784B1 (en) | 2018-06-07 | 2024-01-10 | The Regents Of The University Of Michigan | Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith |
| US10717712B2 (en) | 2018-07-27 | 2020-07-21 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic TRPV1 agonists |
| GB2591681A (en) | 2018-08-29 | 2021-08-04 | Ftf Pharma Private Ltd | Methotrexate pharmaceutical composition |
| US12246042B2 (en) | 2018-08-29 | 2025-03-11 | Myos Corp. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
| US12251405B2 (en) | 2018-10-03 | 2025-03-18 | Myos Corp. | Spray dried follistatin product |
| JP2022509479A (ja) * | 2018-10-24 | 2022-01-20 | セラノヴォ・ベー・フェー | 経口医薬製剤のための深共晶溶媒プラットフォーム |
| NL2021864B1 (en) * | 2018-10-24 | 2020-05-13 | Seranovo B V | Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations |
| WO2020096660A1 (en) | 2018-11-06 | 2020-05-14 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
| EP3906026A4 (en) | 2018-12-31 | 2022-10-19 | Biomea Fusion, LLC | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION |
| WO2020160113A1 (en) | 2019-02-01 | 2020-08-06 | Myos Rens Technology Inc. | Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals |
| EP3937938B1 (en) | 2019-03-15 | 2026-01-28 | Unicycive Therapeutics Inc. | Nicorandil derivatives |
| CA3185209A1 (en) | 2020-07-10 | 2021-01-27 | Alyssa WINKLER | Gas41 inhibitors and methods of use thereof |
| US20240124467A1 (en) | 2020-12-16 | 2024-04-18 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
| AU2022325861A1 (en) | 2021-08-11 | 2024-02-29 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| US20240409558A1 (en) | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| US20250066386A1 (en) | 2021-11-09 | 2025-02-27 | Biomea Fusion, Inc. | Inhibitors of kras |
| TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
| US20250353854A1 (en) | 2022-06-03 | 2025-11-20 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
| CN120265301A (zh) | 2022-10-19 | 2025-07-04 | 迈欧斯公司 | 肌源性化合物 |
| US20250002458A1 (en) | 2023-05-24 | 2025-01-02 | Unicycive Therapeutics Inc. | Salt forms of nicorandil derivative |
| WO2024249950A1 (en) | 2023-06-02 | 2024-12-05 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
| US20250145571A1 (en) | 2023-09-26 | 2025-05-08 | Unicycive Therapeutics, Inc. | Amino acid prodrugs of nicorandil |
| WO2025194102A1 (en) | 2024-03-15 | 2025-09-18 | Unicycive Therapeutics, Inc. | Pyridine modified nicorandil derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US33221A (en) * | 1861-09-03 | Improvement in soap | ||
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| USRE33221E (en) | 1982-04-29 | 1990-05-22 | American Dental Association Health Foundation | Dental restorative cement pastes |
| US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
| EP0319988A1 (en) * | 1987-12-09 | 1989-06-14 | Showa Denko Kabushiki Kaisha | External dermatological composition |
| US5215757A (en) * | 1991-03-22 | 1993-06-01 | The Procter & Gamble Company | Encapsulated materials |
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| AU671811B2 (en) * | 1991-12-18 | 1996-09-12 | Warner-Lambert Company | A process for the preparation of a solid dispersion |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
-
1995
- 1995-06-20 SE SE9502244A patent/SE9502244D0/xx unknown
-
1996
- 1996-06-19 CA CA002225286A patent/CA2225286C/en not_active Expired - Lifetime
- 1996-06-19 ES ES96921197T patent/ES2118677T3/es not_active Expired - Lifetime
- 1996-06-19 AU AU62473/96A patent/AU695622B2/en not_active Expired
- 1996-06-19 EP EP96921197A patent/EP0833611B1/en not_active Expired - Lifetime
- 1996-06-19 DE DE69614689T patent/DE69614689T2/de not_active Expired - Lifetime
- 1996-06-19 NZ NZ311208A patent/NZ311208A/xx not_active IP Right Cessation
- 1996-06-19 WO PCT/SE1996/000806 patent/WO1997000670A1/en not_active Ceased
- 1996-06-19 DK DK96921197T patent/DK0833611T3/da active
- 1996-06-19 JP JP50378997A patent/JP4020331B2/ja not_active Expired - Lifetime
- 1996-06-19 AT AT96921197T patent/ATE204466T1/de active
- 1996-06-19 PT PT96921197T patent/PT833611E/pt unknown
- 1996-06-19 US US08/973,902 patent/US6083518A/en not_active Expired - Lifetime
- 1996-06-19 DE DE0833611T patent/DE833611T1/de active Pending
- 1996-06-20 ZA ZA965237A patent/ZA965237B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE833611T1 (de) | 1999-01-07 |
| CA2225286A1 (en) | 1997-01-09 |
| EP0833611A1 (en) | 1998-04-08 |
| ES2118677T3 (es) | 2001-10-16 |
| JPH11508250A (ja) | 1999-07-21 |
| ATE204466T1 (de) | 2001-09-15 |
| SE9502244D0 (sv) | 1995-06-20 |
| DE69614689T2 (de) | 2002-06-27 |
| ZA965237B (en) | 1997-01-09 |
| JP4020331B2 (ja) | 2007-12-12 |
| CA2225286C (en) | 2003-06-10 |
| NZ311208A (en) | 1999-03-29 |
| DE69614689D1 (de) | 2001-09-27 |
| EP0833611B1 (en) | 2001-08-22 |
| AU695622B2 (en) | 1998-08-20 |
| US6083518A (en) | 2000-07-04 |
| PT833611E (pt) | 2002-01-30 |
| ES2118677T1 (es) | 1998-10-01 |
| AU6247396A (en) | 1997-01-22 |
| HK1008774A1 (en) | 1999-05-21 |
| WO1997000670A1 (en) | 1997-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0833611T3 (da) | Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf | |
| HU76547A2 (en) | Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments | |
| FI103091B1 (fi) | Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi | |
| DE69434626D1 (de) | Transparente flüssigkeit zur verabreichung von verkapselten medikamenten | |
| GB2364304A (en) | Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | |
| PT83872A (de) | Arzneimittel | |
| MY121192A (en) | New compounds. | |
| MY114388A (en) | Multiple unit pharmaceutical preparation | |
| DK0695171T3 (da) | Lyosfærer indeholdende gonadotropin | |
| IS3966A (is) | Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine | |
| NO972128L (no) | 2,2-dikloralkankarboksylsyrer, fremgangsmåte for fremstilling av disse, legemiddel inneholdende disse og anvendelse derav for behandling av insulinresistens | |
| ES2060399T3 (es) | Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento. | |
| PT801559E (pt) | Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama | |
| ATE237316T1 (de) | Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen | |
| ATE173399T1 (de) | Retardtablette mit einem gehalt an diclofenac-na | |
| PT94685A (pt) | Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem | |
| NO179009C (no) | Analogifremgangsmåte for fremstilling av salter av L-alfa-glyserofosforyl-D-myo-inositol | |
| DK1077677T3 (da) | Fremgangsmåde til fremstilling af en biologisk aktiv sammensætning | |
| MX9800243A (es) | Procedimiento para producir principios activos a partir de dispositivos no usados o descartados para la administracion transdermica de principios actios y/o a partir de desechos de fabricacion. | |
| ATE175870T1 (de) | Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen | |
| EP0305194A3 (en) | Veterinary composition | |
| IL117734A (en) | Anellated beta-carbolines their preparation and pharmaceutical compositions containing them | |
| GT198700016A (es) | Procedimiento para la preparacion de n benzoil -n'-fenilu--reas. | |
| UY24851A1 (es) | Derivados de ácidos n-acil-alfa-aminados | |
| ES2149073B1 (es) | Agente atrayente y procedimiento para el control de la polilla euzophera pinguis (haw.). |